Equate Artificial Tears

For the treatment of dry eye symptoms and general ocular irritation, the standard adult dosage of Polyvinyl Alcohol ophthalmic solution is:

• Standard Dosing: Instill 1 to 2 drops in the affected eye(s) as needed.
• Frequency: Many patients find relief with 3 to 4 applications per day. However, because PVA is generally non-toxic and not absorbed systemically, it can be used more frequently if required by the severity of the dryness.
• Severe Dry Eye: In cases of chronic or severe keratoconjunctivitis sicca, a healthcare provider may recommend use every 1 to 2 hours.

Polyvinyl Alcohol is generally considered safe for pediatric use, as its action is topical and mechanical rather than systemic.

• Children (All Ages): The dosage is typically the same as the adult dosage (1 to 2 drops as needed).
• Supervision: Parents or caregivers should administer the drops to young children to ensure proper technique and to prevent the dropper tip from touching the eye, which could cause injury or contamination.
• Consultation: Always consult a pediatrician or pediatric ophthalmologist before starting any new medication in a child, especially if the child is under 6 years of age.

Renal Impairment

No dosage adjustments are necessary for patients with renal (kidney) impairment. Since Polyvinyl Alcohol is not absorbed into the bloodstream, kidney function does not affect the clearance of the drug from the body.

Hepatic Impairment

No dosage adjustments are required for patients with hepatic (liver) impairment. The liver is not involved in the processing or elimination of topically applied Polyvinyl Alcohol.

Elderly Patients

No specific dosage reductions are needed for geriatric patients. In fact, elderly patients often require more frequent dosing due to age-related declines in natural tear production (aqueous deficiency).

Proper administration is crucial to ensure the efficacy of Polyvinyl Alcohol and to prevent infection. Follow these steps:

1. 1Preparation: Wash your hands thoroughly with soap and water.
2. 2Check the Bottle: Ensure the seal is intact. If using a single-use vial, twist off the top.
3. 3Positioning: Tilt your head back or lie down. Look upward.
4. 4The Pocket: Gently pull down your lower eyelid with one finger to create a small pocket.
5. 5Application: Hold the dropper bottle above the eye. Do NOT let the tip of the dropper touch your eye, eyelashes, or any other surface. Squeeze 1 drop into the pocket.
6. 6Closing: Gently close your eye. Do not rub it.
7. 7Punctal Occlusion: Press a finger against the inner corner of your eye (near the nose) for about 1 minute. This prevents the drop from draining into your tear duct and keeps it on the eye longer.

Storage: Store at room temperature (15°C to 30°C or 59°F to 86°F). Keep the bottle tightly closed when not in use. Protect from freezing and excessive heat.

If you miss a dose of Polyvinyl Alcohol, use it as soon as you remember. If it is almost time for your next scheduled application, skip the missed dose and return to your regular routine. Do not 'double up' on drops; the eye can only hold a limited volume of fluid, and the excess will simply run out.

An overdose of Polyvinyl Alcohol in the eye is highly unlikely to cause serious harm. If too many drops are instilled, the excess will simply drain out of the eye.

• Accidental Ingestion: If a child or adult accidentally swallows the solution, contact a Poison Control Center or seek emergency medical care. While PVA itself has low oral toxicity, the preservatives in the solution (such as Benzalkonium Chloride) can cause gastrointestinal upset or irritation if swallowed in large amounts.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. If symptoms persist for more than 72 hours, discontinue use and consult an eye care professional.

Polyvinyl Alcohol is generally very well tolerated, but some users may experience mild, transient effects. These are typically localized to the eye and include:

• Transient Stinging or Burning: A brief sensation of irritation immediately after the drop is instilled. This usually lasts only a few seconds as the solution equilibrates with the natural pH of the eye.
• Blurred Vision: Because PVA increases the viscosity of the tear film, your vision may be slightly 'foggy' or blurry for 1 to 3 minutes after application. Patients should wait for their vision to clear before driving or operating machinery.
• Eye Discharge or 'Crusting': As the water in the drop evaporates, the polymer can sometimes leave a small amount of clear or white dried residue on the eyelashes or in the corners of the eyes.

• Eye Redness (Hyperemia): Some patients may notice a slight increase in the redness of the white part of the eye.
• Increased Sensitivity to Light (Photophobia): A mild discomfort when exposed to bright lights.
• Watery Eyes: Paradoxically, the eye may produce more of its own tears in response to the introduction of a foreign substance.

• Eyelid Swelling (Edema): Puffiness of the eyelids, which may indicate a mild sensitivity to one of the components in the solution.
• Persistent Eye Pain: Any sharp or dull pain that lasts long after the drop has been applied is considered rare and requires medical evaluation.

While Polyvinyl Alcohol is an OTC product, serious reactions can occur, often due to an undiagnosed allergy to the preservatives or the polymer itself.

> Warning: Stop taking Polyvinyl Alcohol, Unspecified and call your doctor immediately if you experience any of these:

• Severe Allergic Reaction (Anaphylaxis): Symptoms include hives, difficulty breathing, swelling of the face, lips, tongue, or throat. This is an extreme medical emergency.
• Vision Changes: Any sudden loss of vision, significant blurring that does not resolve, or seeing 'halos' around lights.
• Signs of Infection: Increased pain, thick yellow or green discharge, and extreme redness, which may indicate that the bottle was contaminated or that an underlying infection is worsening.
• Corneal Abrasion Symptoms: A feeling like something is 'stuck' in the eye that does not go away with the drops.

When used as directed, Polyvinyl Alcohol does not typically cause long-term systemic or ocular damage. However, issues can arise from the preservatives found in multi-dose bottles:

• Medicamentosa (Toxicity): Long-term use (more than 4-6 times daily) of drops containing Benzalkonium Chloride (BAK) can lead to damage of the corneal epithelial cells. This can actually worsen dry eye symptoms over time, a condition known as 'preservative-induced epitheliopathy.'
• Conjunctival Scarring: In very rare, extreme cases of preservative sensitivity, chronic inflammation can lead to changes in the conjunctival tissue.

To mitigate long-term risks, patients requiring frequent lubrication should opt for preservative-free Polyvinyl Alcohol formulations.

There are currently no FDA Black Box Warnings for Polyvinyl Alcohol, Unspecified. It is considered one of the safest ophthalmic lubricants available on the market. It does not carry the risks of systemic toxicity associated with many other pharmacological agents.

Report any unusual symptoms to your healthcare provider. If you experience a serious side effect, you may also report it to the FDA at 1-800-FDA-1088 or online at www.fda.gov/medwatch.

Polyvinyl Alcohol is intended for topical ophthalmic use only. It must not be injected or ingested. While it is a safe, over-the-counter product, its misuse can lead to ocular complications. The most critical safety point is the prevention of contamination. The tip of the dropper must never touch any surface, including the eye itself, as this can introduce bacteria into the bottle, leading to serious eye infections (keratitis) which can cause permanent vision loss.

No FDA black box warnings for Polyvinyl Alcohol, Unspecified. This reflects its high safety profile and the lack of severe systemic risks associated with its use.

Allergic Reactions / Anaphylaxis Risk

Although rare, hypersensitivity to Polyvinyl Alcohol or any of the inactive ingredients (such as preservatives like Benzalkonium Chloride, Disodium EDTA, or Chlorobutanol) can occur. Patients with a known history of multiple chemical sensitivities should review the ingredient list carefully. If you experience itching, swelling, or a rash around the eyes, discontinue use immediately.

Organ-Specific Risks

• Ocular Surface Health: While PVA is used to treat dry eye, excessive use of preserved versions can paradoxically cause 'punctate keratitis' (small areas of cell death on the surface of the eye).
• No Known Systemic Risks: There are no documented risks of hepatotoxicity (liver damage), nephrotoxicity (kidney damage), or cardiotoxicity (heart damage) associated with the topical use of Polyvinyl Alcohol.

Suicidality and QT Prolongation

Polyvinyl Alcohol does not cross the blood-brain barrier in significant amounts and has no effect on neurotransmitters or cardiac electrical conduction. There is no risk of suicidality or QT prolongation associated with this medication.

For most OTC users, formal laboratory monitoring is not required. However, patients using Polyvinyl Alcohol for chronic conditions should have:

• Regular Eye Exams: At least once a year to check corneal health and intraocular pressure.
• Slit-Lamp Examination: A healthcare provider may use a special microscope to ensure the PVA is effectively coating the eye and that no preservative-related toxicity is occurring.

Polyvinyl Alcohol may cause temporary blurring of vision for several minutes after application. Do not drive, use heavy machinery, or perform any activity requiring clear vision until you are certain your vision has returned to its baseline. This is particularly important for those using higher-concentration or 'gel-like' formulations.

There are no known direct interactions between alcohol consumption and the topical use of Polyvinyl Alcohol. However, alcohol is a known systemic dehydrator and can worsen the underlying symptoms of dry eye. Reducing alcohol intake may improve the efficacy of the treatment.

There is no 'withdrawal syndrome' associated with stopping Polyvinyl Alcohol. However, if you are using it to manage a chronic condition like Sjögren's Syndrome, your symptoms (burning, redness, grittiness) will likely return shortly after you stop using the drops. No tapering is required.

> Important: Discuss all your medical conditions with your healthcare provider before starting Polyvinyl Alcohol, Unspecified, especially if you have a history of glaucoma, eye surgery, or chronic eye infections.

There are no documented 'contraindicated' drug combinations where Polyvinyl Alcohol causes a life-threatening systemic interaction. However, in the context of ocular health, it should not be used simultaneously with other eye medications without a specific waiting period.

• Simultaneous Application: Using PVA at the exact same time as another medicated eye drop (such as an antibiotic or glaucoma drop) can dilute the active medication, reducing its efficacy, or wash it out of the eye entirely.

• Soft Contact Lenses: Many Polyvinyl Alcohol formulations contain Benzalkonium Chloride (BAK) as a preservative. BAK can be absorbed by soft contact lenses and may discolor them or cause irritation to the eye tissue trapped under the lens. Patients should remove lenses before instilling drops and wait at least 15 minutes before reinserting them.
• Ophthalmic Ointments: If you are using both a liquid drop (like PVA) and an eye ointment, always use the liquid drop first. Wait at least 10 to 15 minutes before applying the ointment. The ointment creates a barrier that will prevent the PVA drop from reaching the eye surface if applied in the wrong order.

• Other Ophthalmic Demulcents: Using PVA with other lubricants like Carboxymethylcellulose or Hyaluronate is generally safe, but there is little clinical benefit to using them at the same moment. It is better to space them out to provide continuous lubrication throughout the day.

There are no known food interactions with Polyvinyl Alcohol. Unlike oral medications, the absorption of PVA is not affected by the presence of food in the stomach, nor does it interact with specific nutrients like calcium or fats.

There are no documented interactions between Polyvinyl Alcohol and herbal supplements such as St. John's Wort, Ginkgo Biloba, or Valerian root. Because PVA remains on the surface of the eye and does not enter the bloodstream, it does not interact with the metabolic pathways these supplements typically influence.

Polyvinyl Alcohol does not interfere with standard blood or urine tests. However, it may interfere with certain specialized ophthalmic diagnostic tests:

• Fluorescein Staining: If a doctor is performing a fluorescein test to check for corneal scratches, the presence of a thick layer of PVA might temporarily affect the distribution of the dye. Inform your eye doctor if you have applied drops within the hour before your exam.
• Tear Film Osmolarity Tests: Recent use of artificial tears will temporarily alter the results of tests designed to measure the natural salt concentration of your tears.

The primary mechanism for interactions involving Polyvinyl Alcohol is physical/mechanical rather than biochemical. PVA increases the viscosity of the tear film and occupies space in the conjunctival sac. This can delay the absorption of other topical drugs by creating a physical barrier or by increasing the rate of nasolacrimal drainage due to increased fluid volume in the eye.

Management Strategy: To avoid interactions, always follow the '5-minute rule': wait at least 5 minutes between different types of eye drops. If using a gel or ointment, it should always be the last product applied.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including any other eye drops or 'redness relief' products.

Polyvinyl Alcohol has very few absolute contraindications due to its inert nature and lack of systemic absorption. However, the following apply:

• Hypersensitivity: Polyvinyl Alcohol must NEVER be used by individuals with a known, documented allergy to Polyvinyl Alcohol or any of the specific inactive ingredients (preservatives, buffers) in a particular brand's formulation. An allergic reaction in the eye can cause severe swelling and potential damage to the ocular surface.
• Contaminated Product: If the solution becomes cloudy, changes color, or the dropper tip touches a surface, it is absolutely contraindicated for further use. Using contaminated drops can lead to bacterial keratitis, a sight-threatening condition.

These are conditions where the use of Polyvinyl Alcohol requires a careful risk-benefit analysis by a healthcare provider:

• Active Ocular Infection: If you have a bacterial, viral, or fungal infection of the eye (e.g., 'pink eye'), Polyvinyl Alcohol may provide symptomatic relief, but it does NOT treat the infection. Relying on PVA alone could delay necessary antibiotic treatment.
• Post-Surgical Open Wounds: Immediately following certain types of invasive eye surgery, a surgeon may prefer specific sterile, preservative-free formulations over standard OTC PVA drops to avoid any risk of toxicity to the healing tissue.
• Severe Corneal Edema: In conditions where the cornea is significantly swollen, the use of certain formulations of artificial tears might theoretically interfere with the osmotic balance required to clear the fluid, though this is clinically rare.

There is no significant evidence of cross-sensitivity between Polyvinyl Alcohol and other common ophthalmic polymers like Hydroxypropyl Methylcellulose (HPMC) or Polyethylene Glycol. However, if a patient is sensitive to the preservative Benzalkonium Chloride in a PVA product, they will likely react to any other eye drop (glaucoma meds, allergy drops) that uses the same preservative.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Polyvinyl Alcohol, Unspecified, especially if you have had previous adverse reactions to 'artificial tears' or other eye care products.

FDA Pregnancy Category: Not Formally Assigned (Formerly Category C)

Polyvinyl Alcohol is generally considered safe during pregnancy. Because the drug is applied topically to the eye and has negligible systemic absorption, it is highly unlikely to reach the developing fetus in any measurable amount. There are no well-controlled studies in pregnant women; however, decades of clinical use have not suggested any link to birth defects or pregnancy complications.

• Trimester-Specific Risks: There are no known risks specific to the first, second, or third trimesters.
• Recommendation: Pregnant women should ideally use preservative-free formulations to further minimize any theoretical risk of systemic exposure to chemical preservatives.

Polyvinyl Alcohol is considered 'compatible' with breastfeeding. It is not expected to pass into breast milk because it does not enter the mother's bloodstream in significant quantities. There are no known effects on the nursing infant or on milk production. As with pregnancy, preservative-free options are the most conservative choice for nursing mothers.

Polyvinyl Alcohol is frequently used in children to treat irritation from allergies, swimming, or dry environments.

• Approved Age Ranges: There is no specific age cutoff for PVA, but its use in infants should be directed by a pediatrician.
• Special Considerations: Children are more likely to touch the dropper tip to their eye. Caregivers should perform the administration.
• Conditions Not Approved For: PVA should not be used to treat 'sticky eye' in newborns (neonatal conjunctivitis) without a medical evaluation, as this often requires prescription antibiotics.

Dry eye syndrome is significantly more prevalent in the geriatric population due to the natural atrophy of the lacrimal (tear) glands.

• Polypharmacy Concerns: Elderly patients are often on systemic medications (like beta-blockers, antihistamines, or diuretics) that further dry out the eyes. PVA is an excellent adjunctive therapy for these patients.
• Administration Challenges: Patients with arthritis or tremors may find it difficult to squeeze small eye-drop bottles. Using a 'bottle squeezer' aid or having a caregiver assist can ensure the dose is delivered safely.

There are no restrictions for patients with kidney disease. The polymer is not cleared by the kidneys, and even in patients on dialysis, the topical use of PVA is considered safe.

There are no restrictions for patients with liver disease. Polyvinyl Alcohol does not undergo hepatic metabolism and does not pose a risk of hepatotoxicity.

> Important: Special populations require individualized medical assessment. While PVA is safe, the underlying cause of eye irritation in these groups may require different treatments.

Polyvinyl Alcohol (PVA) functions as a demulcent and viscosity-increasing agent. Its molecular structure consists of a repeating vinyl alcohol unit [-(CH2CHOH)n-]. The mechanism is primarily physical:

1. 1Adsorption: The polymer adsorbs onto the corneal surface, creating a hydrophilic (water-loving) coating.
2. 2Tear Film Stabilization: By mimicking the mucin layer, PVA helps the aqueous layer of the tears spread evenly. This prevents the formation of 'dry spots' on the cornea.
3. 3Lubrication: It reduces friction between the eyelid and the cornea during blinking, which is the primary cause of the 'gritty' sensation in dry eye patients.

• Onset of Action: Immediate. Patients typically feel relief within seconds of application.
• Duration of Effect: Short to intermediate. The effect lasts as long as the polymer remains on the ocular surface, typically 15 to 45 minutes, depending on the patient's tear turnover rate.
• Tolerance: There is no evidence of pharmacological tolerance; the drug does not lose its effectiveness over time with repeated use.

| Parameter | Value |

|---|---|

| Bioavailability | Negligible (Topical) |

| Protein Binding | N/A (Not systemically present) |

| Half-life | 5–20 minutes (Ocular surface residence time) |

| Tmax | Immediate (Local effect) |

| Metabolism | None (Systemic) |

| Excretion | Nasolacrimal drainage |

• Molecular Formula: (C2H4O)n
• Molecular Weight: Varies by grade; typically 30,000 to 200,000 Da.
• Solubility: Soluble in water; insoluble in organic solvents.
• Structure: A linear polymer produced by the hydrolysis of polyvinyl acetate. The degree of hydrolysis (the percentage of acetate groups replaced by hydroxyl groups) determines its solubility and viscosity-building properties in ophthalmic solutions.

Polyvinyl Alcohol is classified as an Ophthalmic Lubricant. It is grouped with other demulcents such as Carboxymethylcellulose (CMC), Hydroxypropyl Methylcellulose (HPMC), and Glycerin. Within the therapeutic area of Ophthalmology, these are considered first-line treatments for mild to moderate evaporative and aqueous-deficient dry eye.